<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on January 24, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01521676</url>
  </required_header>
  <id_info>
    <org_study_id>BC-BIO/IPC 2009-005</org_study_id>
    <nct_id>NCT01521676</nct_id>
  </id_info>
  <brief_title>Predictive Clinical and Biological Parameters in Breast Cancer</brief_title>
  <acronym>BC-BIO</acronym>
  <official_title>Research of Predictive Clinical and Biological Parameters in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research of predictive clinical and biological factors in breast cancer :

      genomic, proteomic, mutation
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>molecular alteration in breast cancer</measure>
    <time_frame>average of 4 weeks after diagnosis</time_frame>
    <description>gene expression level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relation between molecular alteration and clinical and histological characteristics</measure>
    <time_frame>up to 3 years</time_frame>
    <description>hazard ratio between molecular alteration and clinical and histological characteristics</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>blood and tumor sample</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>molecular alteration</intervention_name>
    <description>research of molecular alteration</description>
    <arm_group_label>breast cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  breast cancer

          -  age &gt; 18

          -  signed informed consent

        Exclusion Criteria:

          -  emergency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole TARPIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jihane PAKRADOUNI, PharmD PhD</last_name>
    <phone>33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole TARPIN, MD</last_name>
      <phone>33491223778</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Carole TARPIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte-Musse</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric VIRET, MD</last_name>
      <email>frederic.viret@ch-toulon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.institutpaolicalmettes.fr</url>
    <description>official web site of the sponsor</description>
  </link>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 26, 2016</lastchanged_date>
  <firstreceived_date>December 22, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
